Robert Frederich
Overview
Explore the profile of Robert Frederich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
2512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, et al.
Kidney Dis (Basel)
. 2025 Mar;
11(1):63-74.
PMID: 40028005
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease. The aim...
2.
Cosentino F, Dagogo-Jack S, Frederich R, Cannon C, Cherney D, Mancuso J, et al.
Diabetes Obes Metab
. 2024 Dec;
27(2):583-594.
PMID: 39696829
Aim: To assess weight loss and cardiorenal outcomes by baseline body mass index (BMI) in VERTIS CV. Methods: Patients with type 2 diabetes and atherosclerotic cardiovascular (CV) disease were randomized...
3.
Amin N, Frederich R, Tsamandouras N, Haggag A, Schuster T, Zmuda W, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):215-227.
PMID: 39415344
Aim: The aim was to investigate the effects of lotiglipron, a once-daily, oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity. Materials And...
4.
Odutayo A, Cosentino F, Pratley R, Dagogo-Jack S, McGuire D, Frederich R, et al.
Diabetes Obes Metab
. 2024 Jun;
26(8):3478-3481.
PMID: 38840474
No abstract available.
5.
Wang S, Frederich R, Mancuso J
Ther Innov Regul Sci
. 2023 Oct;
58(1):114-126.
PMID: 37805643
We have explored several statistical approaches to impute missing time-to-event data that arise from outcome trials with relatively long follow-up periods. Aligning with the primary estimand, such analyses evaluate the...
6.
Cherney D, Cosentino F, McGuire D, Kolkailah A, Dagogo-Jack S, Pratley R, et al.
Kidney Int Rep
. 2023 Apr;
8(4):746-753.
PMID: 37069970
Introduction: In the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881), patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) were randomized (1:1:1)...
7.
Ji L, Liu J, Jin Xu Z, Wei Z, Zhang R, Malkani S, et al.
Diabetes Ther
. 2023 Feb;
14(2):319-334.
PMID: 36763328
Introduction: The efficacy and safety of ertugliflozin have not been well characterized in Asian populations with type 2 diabetes (T2D) and overweight or obesity as defined by the Chinese Diabetes...
8.
Dagogo-Jack S, Frederich R, Liu J, Cannon C, Shi H, Cherney D, et al.
J Clin Endocrinol Metab
. 2023 Jan;
108(8):2042-2051.
PMID: 36702781
Context: VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Objective: The aim of these analyses was to assess the...
9.
Kim J, Bhatt D, Dagogo-Jack S, Cherney D, Cosentino F, McGuire D, et al.
Diabetes Obes Metab
. 2023 Jan;
25(5):1398-1402.
PMID: 36594154
No abstract available.
10.
Corbin K, Dagogo-Jack S, Cannon C, Cherney D, Cosentino F, Frederich R, et al.
Diabetes Obes Metab
. 2022 Nov;
25(3):758-766.
PMID: 36394384
Aim: To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study. Materials And Methods: Patients with type 2 diabetes and...